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18F-VC701-PET and MRI in the in vivo
neuroinflammation assessment of a mouse
model of multiple sclerosis
Sara Belloli1,2,3, Lucia Zanotti4, Valentina Murtaj2,5,6, Cristina Mazzon7,8, Giuseppe Di Grigoli1,2, Cristina Monterisi6,
Valeria Masiello6, Leonardo Iaccarino9, Andrea Cappelli10, Pietro Luigi Poliani11, Letterio Salvatore Politi2,12,13†
and Rosa Maria Moresco1,2,6*†
Abstract
Background: Positron emission tomography (PET) using translocator protein (TSPO) ligands has been used to
detect neuroinflammatory processes in neurological disorders, including multiple sclerosis (MS). The aim of this
study was to evaluate neuroinflammation in a mouse MS model (EAE) using TSPO-PET with 18F-VC701, in
combination with magnetic resonance imaging (MRI).
Methods: MOG35-55/CFA and pertussis toxin protocol was used to induce EAE in C57BL/6 mice. Disease progression
was monitored daily, whereas MRI evaluation was performed at 1, 2, and 4 weeks post-induction. Microglia
activation was assessed in vivo by 18F-VC701 PET at the time of maximum disease score and validated by
radioligand ex vivo distribution and immunohistochemistry at 2 and 4 weeks post-immunization.
Results: In vivo and ex vivo analyses show that 18F-VC701 significantly accumulates within the central nervous
system (CNS), particularly in the cortex, striatum, hippocampus, cerebellum, and cervical spinal cord of EAE
compared to control mice, at 2 weeks post-immunization. MRI confirmed the presence of focal brain lesions at
2 weeks post-immunization in both T1-weighted and T2 images. Of note, MRI abnormalities attenuated in later
post-immunization phase. Neuropathological analysis confirmed the presence of microglial activation in EAE mice,
consistent with the in vivo increase of 18F-VC701 uptake.
Conclusion: Increase of 18F-VC701 uptake in EAE mice is strongly associated with the presence of microglia
activation in the acute phase of the disease. The combined use of TSPO-PET and MRI provided complementary
evidence on the ongoing disease process, thus representing an attractive new tool to investigate neuronal damage
and neuroinflammation at preclinical levels.
Keywords: EAE monophasic model, Neuroinflammation, TSPO-PET, MRI, Multiple sclerosis
Background
Multiple sclerosis (MS) is the most common disabling
neurological disease of young adults, affecting 2.3 million
people worldwide and leading, in most cases, to severe and
irreversible clinical disability [1]. Despite the increasing
number and efficacy of novel therapeutic options, curative
treatments for MS patients are lacking. This chronic
inflammatory disorder is characterized by demyelination
and axonal damage, culminating in the development of
multifocal sclerotic plaques [2]. Different peripheral im-
mune system cells, including T cells, B lymphocytes, and
macrophages infiltrate into the CNS, eliciting neuroinflam-
mation, oligodendrocyte death, and axonal damage [3].
Focal demyelinated plaques surrounded by regions express-
ing inflammatory markers and gliosis represent the core
neuropathological features of MS. Lesions are located in
multiple white matter [4] areas like the optic nerves, spinal
cord, brainstem, cerebellum, periventricular white matter,
and corpus callosum [5]. However, focal plaques have been
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described also in gray matter (GM) [6]. Axonal damage
represents another pathological hallmark of MS and may
occur independently of chronic demyelination [7].
Diagnosis of MS is based on clinical presentation of
patients and instrumental data such as cerebro-spinal
fluid (CSF) examination and magnetic resonance im-
aging (MRI) [8]. MRI procedures and pathological
correlates have been standardized according to the
recommendations indicated in McDonald criteria
2010, recently revised by the MAGNISM group [9].
MS lesions are defined using gadolinium-enhanced-T1
or T2-weighted MRI sequences. Despite the diagnostic
power, conventional MRI is not able to fully describe
the complex neuropathological modifications associ-
ated with MS or explain the biological meaning of
abnormalities present in “normal appearing” GM or
WM regions [10]. The use of positron emission tom-
ography (PET) enables the in vivo quantification of
selected biological processes depending on the radio-
pharmaceutical adopted. The isoquinoline carboxa-
mide 11C-(R)-PK11195, as well as second generation
radiopharmaceuticals targeting the 18 kDa-translocator
protein (TSPO) expressed on microglial cells, allow in vivo
imaging of brain inflammation in a number of neurode-
generative and neuroinflammatory disorders, including
MS [11–14].
In MS, microglia activation seems to play a dual role,
both favoring chronic inflammation and neurodegenera-
tion through the modulation of T cells and release of
reactive species, proteolytic enzymes, or other neuro-
toxic molecules [15, 16] and promoting re-myelination
and oligodendrocyte differentiation [17]. Clinical studies
showed increased 11C-(R)-PK11195 binding not only in
Gd-T1-enhanced lesions or in T2 hyperintense areas of
patients [12] but also in T1 hypodense regions or
normal-appearing WM or GM [18, 19]. For these rea-
sons, the combined use of MR and PET imaging could
represent a unique tool to improve pathological and
diagnostic characterization of MS [20].
TSPO ligands have been also used in the experimental
autoimmune encephalomyelitis (EAE), a well-established
animal model for MS [21] that displays several neuro-
pathological features of MS, including microglial activa-
tion. In some of these studies, the distribution of TSPO
radioligands has been cross-validated with post mortem
immunohistochemistry analysis [22–25]. Despite the
interest, preclinical data deriving from both TSPO-PET
and MRI in rodent models of MS are lacking [25]. To
explore the potential advantage of a multimodal imaging
approach also in preclinical studies, here, we describe
the combined use of 18F-VC701-PET, previously devel-
oped and validated in our facility [26], and Gd-T1 and
T2 MR sequences in a murine EAE model [27]. This
study allowed to obtain complementary results and to
investigate novel diagnostic approaches, especially in light
of the recent development of the new hybrid PET/MRI
scanners [28].
Methods
Radiotracer
18F-VC701 was prepared with the automated synthesizer
TRACERLAB FXFN (GE Healthcare, Milan, Italy) as pre-
viously described. In brief, [18F]F− was produced with
the 18O(p,n)18F nuclear reaction by irradiation of
[18O]water. After an anhydrification step, the labelling
was performed with the precursor VC622 (3 mg) in an-
hydrous DMSO at 140 °C for 20 min. The reaction
mixture was injected in semi-preparative HPLC for the
purification. The fraction corresponding to 18F-VC701
was collected in sterile water and the product recovered
by solid-phase extraction on pre-activated Sep-Pak tC-
18 cartridge. 18F-VC701 eluted with ethanol (0.7 mL)
and diluted with a saline solution (10 mL) for the final
formulation. Radiochemical purity of 18F-VC701 > 98%
was requested for mice experiments.
Animals
C57BL/6J mice were purchased from Charles River. Age-
matched female, 8- to 12-weeks-old, were used in all
experimental procedures. Animal were maintained and
handled in compliance with the institutional guidelines for
the care and use of experimental animals (IACUC), which
have been notified to the Italian Ministry of Health and
approved by the Ethics Committee of the San Raffaele
Scientific Institute (Prot. N. SK552/2012 D.lsg. 116/1992
and N. 722/2016-PR D.lsg. 26/2016).
EAE model
C57BL/6J mice were immunized subcutaneously with
100 μg MOG35–55 (MEVGWYRSPFSRVVHLYRNGK,
AnaSpec Inc), in incomplete Freud adjuvant (IFA,
Sigma) containing 400 μg of heat-inactivated Mycobac-
terium tuberculosis H37 RA (Difco) and received two
intravenous injections (i.v.) of 350 ng of pertussis toxin
(List Biological Laboratories Inc), on day 0 and day 2
after immunization. The effect of immunization was
checked using a standard clinical scale ranging from 0 to
5 [29] as follows: 0, asymptomatic; 1, limp tail; 2, limp
tail and hind limb weakness; 3, partial hind limb paraly-
sis; 4, complete hind limb paralysis; 5, moribund state,
death (Fig. 1).
Study design
A total of 40 mice were included in this study. For EAE
mice: 27 mice were immunized as described in the pre-
vious paragraph; one mouse did not manifest clinical
signs and was excluded and one had a severe reaction
and died after immunization. The remaining 25 EAE
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mice were included in the study: 15 animals were dedi-
cated to in vivo and ex vivo diagnostic imaging and 10
to immunohistochemistry (IHC) analysis. In particular,
seven mice were sacrificed in ex vivo VC701 biodistribu-
tion experiment at 14 days post-infection (p.i.); four
mice performed the in vivo longitudinal MRI study at 7,
14, and 28 days. The same group of animals underwent
a PET scan at day 14 p.i. These animals plus additional 3
performed an ex vivo study with [18F]VC701 at 30 p.i.
Time-activity curve (TAC) study was performed on a
separate mouse to define PET acquisition time frame.
For healthy controls, 15 control animals were also
included, 9 animals for in vivo and ex vivo imaging and
6 for immunohistochemistry (IHC) analysis.
MRI imaging
Disease progression was monitored through longitudinal
MRI imaging at different time points after immunization,
with T1-Gd and T2-weighted sequences using a small-
animal dedicated 7 Tesla MR scanner (Bruker Biospec 30/
70, Ettlingen, Germany) and a four-channel mouse-head
dedicated phased-array coil.
EAE (n = 4) animals at 7, 14, and 28 days post-
immunization and control mice (n = 3) were anesthetized
via intra peritoneal (i.p.) injection of tribromoethanol
(Sigma Aldrich S.r.l., Italy) at 1.7% (20 μg/g) concentration
prior to intravenous (i.v.) administration of Gadobutrol
(Gadovist®, Bayer S.p.A., Italy) 0.3 mmol/kg, based on ani-
mal weight, in order to assess cerebral lesions. The animals
were positioned prone on the dedicated heated apparatus.
The image acquisition was performed on coronal plane
using the following sequence protocol:
 Spin Echo T1 (time of repetition 526 ms, echo time
8 ms, voxel size 100 × 100 × 700 micron);
 RARE T2 (time of repetition 3007 ms, echo time
36 ms, voxel size 100 × 100 × 700 micron).
The brain lesions’ volumes were quantified manually
using the manufacturer’s software (Paravision 5.1,
Bruker, Ettlingen, Germany).
Ex vivo biodistribution and in vivo PET studies with the
TSPO radioligand 18F-VC701
The time course of TSPO signal in EAE mice was evalu-
ated by tissue sampling analysis at 14 (EAE, n = 7) and
30 days post-immunization (EAE, n = 7). EAE animals
were compared with 9 aged match healthy animals. Ani-
mals were injected in the tail vein with 4.0 ± 0.9 MBq of
18F-VC701 and sacrificed 240 min later. This time frame
was selected on the basis of previous kinetics data on
rats [26] and on a brain kinetic study on one EAE mouse
showing a slight but progressive increase of brain radio-
activity concentration, particularly in the cerebellum that
is the brain region more affected in EAE mice. The in-
crease in 18F-VC701 uptake measured as percentages of
the injected dose per gram and cerebellum to cortex ratio
is maximum between 2 and 4 h p.i. (see Additional file 1:
Figure S1). Plasma was separated by centrifugation and
counted with a blood sample in a gamma counter (LKB
Compugamma CS1282, Wallac). Immediately after sacri-
fice, discrete areas as cortex, striatum, hippocampus, cere-
bellum, cervical enlargement, thoracic, and lumbar spinal
cord were sampled and washed with cold saline. Samples
were placed in pre-weighed tubes and counted. Radio-
activity concentrations were calculated as percentages of
the injected dose per gram of tissue (%ID/g) and
expressed as ratio between interested area and plasma
(%ID/g/%ID/g).
Four EAE mice and 3 healthy controls that underwent
the longitudinal MRI study were evaluated also with
PET at the time of maximum MRI-based abnormalities,
i.e., 14 days post-immunization. 18F-VC701 was i.v.
injected in a tail vein (5.9 ± 0.7 MBq). Each mouse was
anesthetized with isoflurane in air (induction, 4%; main-
tenance, 2%) 240 min later, positioned prone on the PET
scanner (YAP-S-PET II, ISE, Italy) bed, and scanned for
30 min (six dynamics frames of 5 min each). For the EAE
mouse that underwent kinetic for the definition of the
better time frame of tracer study, we acquired brain from
18F-VC701 i.v. injection up to 240 min. After reconstruc-
tion, correction for injected dose, and radioisotope decay,
PET images were quantified using dedicated phantom and
co-registered with MRI for the analysis with PMOD 3.2v
(PMOD Technologies Ltd., Switzerland) software. 18F-
VC701 radioactivity concentration was calculated using
region of interest (ROI) analysis. More specifically, circular
macro-ROIs were hand-drawn on the forebrain, midbrain,
cerebellum, cervical enlargement, thoracic and lumbar
Fig. 1 Clinical score of MOG35-55/CFA-immunized (EAE) mice.
Graphical representation of clinical score of EAE mice evaluated daily
after disease induction; mean scores ± SEM
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spinal cord, and muscle in the MRI images and then ap-
plied on the co-registered PET images on three consecu-
tive transaxial slices. Radioactivity concentrations were
expressed as a percentage of injected dose per gram (%ID/
g) and divided for radioactivity concentration in muscle
(%ID/g/%ID/g). The evaluation of the relative distribution
of TSPO-PET and MRI (T1 post-gadolinium enhancing
and T2 hyperintensities) abnormalities was performed by
visual inspection of the co-registered brain images of the
four EAE mice.
Histology and immunohistochemistry
Mice (5 EAE and 3 control mice per time point) were
perfused with PBS followed by 4% paraformaldehyde
(PFA). Two-micrometer-thick paraffin-embedded tissue
sections from brains and spinal cords have been used for
either routine pathological evaluation by hematoxylin
and eosin (H&E) staining and immunohistochemistry
(IHC). The following primary antibodies were used:
rabbit anti-Iba-1 (1:300, Wako), rabbit anti-GFAP (1:200,
Dako), and rat anti-MBP (1:50, Chemicon, Thermo
Fisher Scientific, USA). Immunostaining has been re-
vealed by Real EnVision Rabbit HRP or Rat-on-Mouse
HRP (Biocare Medical, USA) and diaminobenzidine
(DAB, Dako, Agilent Technologies, Italy) and counter-
stained with hematoxylin. Digital images have been ac-
quired by Olympus DP70 camera mounted on Olympus
Bx60 microscope, using CellF Imaging software (Soft
Imaging System GmbH, Olympus, Italy).
Quantification of neuropathological features, although
present both in the brain and spinal cord sections, has
been performed in the spinal cords since it is highly re-
producible and well established in the literature [30].
The degree of inflammation was expressed as percentage
of infiltrated area over the total spinal cord section and
demyelination was evaluated by measuring the percent-
age of demyelinated area over the total white matter area
for each spinal cord section. An average of 8–10 spinal
cord sections for each mouse was evaluated. Macro-
phage infiltration/microglial activation have been evalu-
ated by assigning a semi-quantitative score to Iba-1
immunostaining and graded as follows: 0, none; 1, low;
2, moderate; 3, high [30].
Statistical analyses
Differences in radioactivity concentration between re-
gional distribution of 18F-VC701 in EAE and control
animals were evaluated using the Student t test, defining
a statistical significance threshold of p < 0.05. Mann-
Whitney test was performed for MRI data of brain lesion
volume measured through T1-gadolinium-enhanced and
T2-weighted images (Software: GraphPad Prism 5.0).
Results
Immunized mice showed motor signs and MRI
abnormalities typical of EAE that peaked at 14 days
post-treatment
The vast majority of the immunized mice developed
signs of EAE. The disease onset ranged approximately
between day 10 and day 11 p.i. with a peak of clinical
manifestations at 14–15 days p.i. One mouse did not
manifest clinical signs, and one died after immunization.
Despite a high variability of response, considering the
whole group of mice, disease scores remained fairly
stable over time (Fig. 1). At 7 days after disease induc-
tion, EAE mice T1 and T2 images showed no differences
when compared to the control group, consistent with a
previous report [27]. In the acute disease phase (14 days
p.i.), lesions could be detected on both T2-weighted and
post-contrast T1-weighted sequences in the regions in-
cluding periventricular white matter, corpus callosum,
thalamus, hippocampus, midbrain, pons, and cerebellum
(Fig. 2a). At this time point, T2 hyperintense lesions
overlapped with Gd-T1 enhancement in the majority of
brain regions. Twenty-eight days p.i., signals detected by
both T1/T2-weighted images decreased in the majority
of regions (Fig. 2b; see panel (c) for control mouse).
However, in the periventricular white matter and in the
ventral aspect of the hippocampus, T2 alterations were
still evident. Overall, these imaging data are consistent
with the motor signs of immunized mice. The lesion vol-
ume measured on T1-weighted images at 14 days p.i.
showed great variability (Fig. 3a), likely mirroring the
known variability in the immunization. Belatedly (28 days
p.i.), the T1-weighted lesion volume values decreased
progressively to zero in all tested mice. The total brain
lesion volume on T1-weighted images was lower when
compared to that of T2-weighted images (Fig. 3b). T2-
weighted images indeed showed the pattern of more
concurrent events such as inflammation, edema, and
demyelinating process, without however the possibility
of differentiating them.
An increase of regional uptake of 18F-VC701 and Iba-1
microglia/macrophage marker was present in both spinal
cord and brain regions of EAE mice
18F-VC701 allowed detecting ex vivo and in vivo inflam-
matory reaction in the brain and spinal cord of EAE mice
at the time of maximum increase of clinical signs. Mice
were analyzed at 4 h after tracer injection to maximize
signal to background ratio (see the “Methods” section).
Tissue sampling analysis revealed a significant in-
crease of radioactivity concentration in the EAE mice
as compared to control at the level of cortex and cere-
bellum (p < 0.05), and striatum, hippocampus, cervical en-
largement, and thoracic and lumbar spinal cord (p < 0.01)
at 14 days p.i. Radioactivity distribution progressed towards
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Fig. 2 Magnetic resonance imaging (MRI) longitudinal study of a representative EAE mouse and healthy control. a Selected coronal MRI
images acquired at 14 days p.i. showing focal lesions in T2-weighted and post-contrast T1-Gd-weighted images in different brain areas
including hippocampus, corpus callosum, external capsule, and periventricular white matter. b Coronal T2 and T1-Gd MRI images acquired
at 28 days p.i., representing the same brain coordinates of those shown in a. T2-enhanced regions are limited to the periventricular white
matter and in the ventral aspect of hippocampus. EAE selected mouse exhibit 2.5 as clinical score at acute time point and 0 at late time
point. c Selected coronal T2-weighted and post-contrast T1-Gd-weighted MRI images of a healthy control mouse
Fig. 3 Magnetic resonance lesion volume measured in EAE mice brain. a T1-Gd-enhanced lesion volumes in four EAE mice measured at different
time points after immunization. b T2 lesion volumes obtained in the same four EAE mice analyzed with T1-Gd MRI at different time points after
immunization. Lesion volumes are expressed in millimeter cube and represented as single point including median; statistical analysis is performed
using Mann-Whitney test
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a cranio-caudal direction, with lower values in the
cortex and higher values in the lumbar trait of the
spinal cord (Fig. 4a).
At 30 days p.i., we observed a trend similar to that ob-
served for the acute phase, although significant differences
in 18F-VC701 uptake between EAE and WT (p < 0.05)
only in the spinal cord and in discrete brain regions like
the cerebellum.
In vivo PET analysis performed 14 days p.i. was consist-
ent with the findings obtained from ex vivo experiments.
Macro-ROI analysis showed a progressive increase of 18F-
VC701 uptake towards cranio-caudal direction, with the
highest increase of radiotracer uptake localized in lum-
bar trait of the spinal cord, and significant increase
compare to controls observed in midbrain (p < 0.01)
and cerebellum, cervical enlargement, and thoracic
spinal cord (p < 0.05, Fig. 4c). Coronal and sagittal PET
images of the three spinal cord traits considered are
shown in Fig. 4d and Additional file 2: Figure S2,
respectively. At visual inspection, EAE mice displayed
heterogeneous clusters of increased radioactivity uptake
in discrete brain regions including anterior cortex, mid-
brain, cerebellum, cervical enlargement and thoracic
spinal cord when compared to control mice (see Figs. 4d
and 6 and Additional file 2: Figure S2). Histopatho-
logical analysis of spinal cords and brains confirmed
the association between the increased clinical score ob-
served in immunized mice and the neuropathological
features. Of note, at 2 weeks post-immunization, H&E
staining revealed severe acute inflammation, particu-
larly within the spinal cord, and preferentially distrib-
uted along the meninges and in perivascular areas
(Fig. 5a and left graph). Myelin damage (Fig. 5b) and
reactive gliosis (data not shown) were in line with the
clinical score. However, during the chronic phase (at
4 weeks post-immunization), inflammation was barely
detected (Fig. 5d), whereas demyelination, when quanti-
fied on myelin basic protein (MBP) immune-stained
Fig. 4 Ex vivo (a) and in vivo (b) distribution of 18F-VC701 in several regions of the central nervous system, in control and EAE mice. Regional
distribution data are expressed as tissue to plasma ratios measured ex vivo at 14 (a) and 30 (b) days post-immunization. Regional distribution
measured in vivo with PET at 14 days after immunization are expressed as tissue to muscle ratio (c); data are calculated as mean ± SD value; test
T, *p < 0.05 vs controls. Representative PET images from the spinal cord of an EAE mouse with clinical score 2 at 14 days after immunization and
healthy control mice injected with 18F-VC701 are shown (d)
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sections, was significantly lower as compared to control
mice at 2 weeks p.i. (Fig. 5e and middle graph), mainly
due to inflammatory clearance and re-myelination. This
data mirrored the clinical scores as well. Of note, GFAP
immunostaining highlighted diffuse and intense gliosis
(data not shown). Accordingly, immunostaining for the
microglia/macrophage-specific marker Iba-1 showed that
activated microglia and macrophages were highly repre-
sented in the spinal cord at the peak of the disease
(2 weeks p.i.), while during the chronic phase (4 weeks
p.i.), EAE mice showed a significant reduction of the
macrophage/microglia infiltration (Fig. 5c, f; right graph).
Activated microglia show a typical hypertrophic morph-
ology (inset from panel (c)), while at 4 weeks p.i. microglia
shows the classical feature of resting cells with thin ramifi-
cation and scarce cytoplasm (inset from panel (f)). Iba-1
staining at 14 days revealed the presence of microglial
cells/macrophage infiltration in different brain regions in-
cluding the brain stem, the cerebellum, the hippocampus
and the cortex (Fig. 5g). According to the present conver-
ging PET, MRI, and ICH data, inflammation and tissue
damage were more severe in the spinal cords than in the
brain and followed a cranio-caudal gradient, with the lum-
bar spinal cord sections being the more affected.
18F-VC701-PET and MRI showed partially overlapping but
complementary results in EAE mouse brain
PET signals in EAE mice only partially co-localized with
damaged brain regions detected with MRI. In one mouse,
PET evidence and clinical assessments were negative des-
pite the presence of lesions on T2-weighted images. On
the contrary, other mice showed highly concordant PET-
and MRI-based evidence in multiple brain regions, i.e.,
hippocampus (3/4), hypothalamus (2/4), midbrain (3/4),
corpus callosum (2/4) pons, and cerebellum both (4/4).
However, and particularly for the hippocampus, the distri-
butions of PET and MRI alterations were not completely
overlapped (14 days p.i., Fig. 6, Additional file 3: Figure S3).
Otherwise, we observed clusters of significant 18F-VC701
uptake in absence of MRI T1 or T2 signals in other regions,
such as in the striatum, cortex, and cerebellum. Lastly, no
increases of radioactivity concentrations were detected in
Fig. 5 Histology and immunohistochemistry analysis. H&E staining of lumbar spinal cord sections of EAE mice sacrificed at 14 and 28 days p.i.
(a, d; left graph). The degree of inflammation was higher during the acute phase of the disease (14 days p.i.), while barely detected in mice at
28 days p.i. Magnification shown in the inset from a revealed foci of inflammation (indicated by asterisks in the panel). Demyelination followed
the same trend than inflammation passing from 14 to 28 days p.i. (b, e; middle graph), as indicated by arrows. At 2 weeks p.i. Iba-1 positive
microglia and macrophage cells were highly represented, while scarcely detected at 4 weeks p.i. (c, f; right graph). Inset from c and f shows
details on different microglia morphology during the two disease phases. Images a, b, d, and e, ×2 original magnification; images c and f, ×20
original magnification; insets, ×60 original magnification. Iba-1 positive staining images at different magnification (×20 and ×40) obtained from
the cerebellum, cortex, hippocampus, and brain stem representative of one EAE mice sacrificed at 14 days p.i.. Iba-1 positive staining is visible in
all brain regions but is particularly evident in cerebellum, brainstem, and hippocampus (g)
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MRI-positive areas such as the thalamus and periventricu-
lar white matter (Table 1).
Discussion
In the present study, we evaluated the feasibility of using
18F-VC701-PET to detect and follow microglia activation
evolution in a monophasic MS mouse model obtained
after MOG35-55 peptide treatment. Additionally,
18F-VC701
TSPO-PET was coupled with conventional T1-gadolinium-
enhanced and T2 MRI imaging to evaluate the potential
additive effect of combined PET and MRI techniques for
the identification of EAE-related damages.
Clinical evaluation showed typical neurological defi-
cits, starting around 11–12 days p.i. and peaking at
14 days p.i. In line with previous results from the same
EAE animal model, we detected a slight and not signifi-
cant reduction of motor signs at later disease phase [30].
MRI scans showed the presence of focal brain lesions in
the acute phase of disease (i.e., at 14 days p.i.), detected
on both T2-weighted and post-contrast T1-weighted
sequences, in several brain regions, including the peri-
ventricular white matter, thalamus, corpus callosum,
hippocampus, pons, and cerebellum. Of note, the max-
imum total lesion volume was observed on both post-
contrast T1- and T2-weighted sequences at the same
time point. At later disease phases, we observed a net
Fig. 6 In vivo PET and MRI images representative of a healthy control and one of the EAE mouse (clinical score at 14 d.p.i. corresponding
to 2 and 2.5 at 28 d.p.i.) evaluated at 14 days post-immunization. a 18F-VC701 PET and MRI co-registered coronal images of a healthy
control; b 18F-VC701 PET and MRI co-registered coronal images from a EAE mice. c Corresponding MRI post-gadolinium T1-weighted
(post-Gd T1-w) and T2-weighted (T2-w) images of the animal shown in b. Damaged brain areas are indicated by arrows. Some of these
areas are overlapped in both PET and MRI (left hippocampus, white arrow); others are evident only in PET (bilateral hippocampi, red
arrows) or in post-contrast MRI (yellow arrow) images. In the ventral part of coronal images of both control and EAE animals is present a
marked region of radioactivity uptake deriving from non-specific accumulation of the tracer in extra-cerebral regions
Table 1 Table summarizing lesions detected by visual
inspection of co-registered brain images of the four EAE mice
studied with PET/MRI performed at 14 days post-immunization
EAE lesion
localization
EAE lesion
detected
by T2w MRI
EAE lesion
detected by
T1/Gd MRI
EAE lesion
detected by
F18VC-701 PET
Periventricular white matter 4/4 + 4/4 + 0/4 +
Thalamus 1/4 + 1/4 + 0/4 +
Cortex 1/4 + 1/4 + 3/4 +
Striatum 2/4 + 2/4 + 3/4 +
Hypothalamus 2/4 + 2/4 + 2/4 +
Hippocampus 3/4 + 3/4 + 3/4 +
Corpus callosum 2/4 + 2/4 + 2/4 +
Periaqueductal gray matter 1/4 + 1/4 + 1/4 +
Midbrain 3/4 + 3/4 + 3/4 +
Pons 3/4 + 3/4 + 4/4 +
Cerebellum 1/4 + 1/4 + 4/4 +
The table indicates overlapping lesion in this two different imaging modalities
on acute phase of the disease; +: detected
T1/Gd T1-weighted image with gadolinium contrast agent, T2w T2-weighted
MRI, PET imaging with 18F-VC701 tracer
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reduction of T1 lesion burden, with T2- and T1-enhanced
signals only partially overlapping, confirming the presence
of demyelination, edema, or axonal damages also in the
absence of inflammatory cell infiltration. As we previously
observed, this discordance was particularly evident at later
disease phase, where in the same brain regions we ob-
served T2 hyperintensities in absence of any gadolinium
uptake on T1-weighted images [27].
Both ex vivo tissue sampling and in vivo PET studies
indicate that 18F-VC701 binding increases in different
brain regions and in the spinal cord of EAE mice when
macro-regions were used to quantify the signal. More
specifically, using post mortem analysis, we found a
maximum and significant increase of radioactivity con-
centration at 14 days p.i., with a regional distribution fol-
lowing a rostro-caudal positive gradient. A similar trend
was present also when 18F-VC701 binding was quanti-
fied in vivo. However, PET data revealed a large hetero-
geneity in 18F-VC701 among animals, with cluster of
increased radioactivity uptake localized in discrete brain
regions. Post mortem tissue sampling studies indicated
that, at 30 days p.i., a significant increase of radioactivity
was present only in the striatum, cerebellum, and spinal
cord; in these regions, the levels of radioactivity concen-
tration were still high. The pattern of tracer uptake was
in line with that described by other TSPO-PET studies
performed with different radioligands and EAE models,
showing a cranio-caudal increasing gradient [23]. Finally,
also Iba-1 immunostaining measured post mortem was
present both in the spinal cord and in the brain regions
displaying higher uptake of 18F-VC701 [20].
To date, few imaging studies with TSPO ligands have
been published in mouse and rat EAE models [22–24], and
none of them combined conventional diagnostic MRI se-
quences with TSPO-PET. The only preclinical study asso-
ciating TSPO-PET with MRI used T1-weighted sequences
to focus on the longitudinal evaluation of ventricles vol-
ume enlargement, although not evaluating their relation
with PET signal [25].
In our study, 18F-VC701 PET and MRI performed at the
same day p.i. showed consistent but not overlapping results,
confirming that also in the EAE model, the two image mo-
dalities may provide complementary information. In EAE
animals, co-registered PET-MRI images showed TSPO
signals also in regions lacking focal MRI abnormalities, par-
ticularly in gray matter regions including cortex, striatum,
and cerebellum. These results although based on a small
cohort of mice are in agreement with what is observed in
patients. The presence of TSPO-PET signal outside MRI
lesions was first described by Banati et al. in 2000 and then
confirmed in other clinical studies [12, 31].
As previously stated, T1 and T2 MRI signals have differ-
ent biological correlates including blood-brain barrier
(BBB) leakage, edema, demyelination, gliosis, necrosis, or
peripheral inflammatory cell infiltration [9]. In particular,
gadolinium enhancement in T1-weighted MRI images
indicates the presence of leakage in endothelial BBB and is
considered in clinical routine as a surrogate marker of per-
ipheral cell infiltration into the brain and representative of
active lesions. On the contrary, an increased signal in T2
reflects different pathological events, not limited to the
identification of focal areas of inflammatory edema, but also
including astrogliosis, demyelination, axonal damage, or
subtle BBB disturbance not detected with gadolinium.
TSPO-PET specifically reflects the presence of acti-
vated glial cells [32] and mainly those belonging to
monocyte lineage, that in MS are mainly represented by
perivascular macrophages or resident microglia. There-
fore, increases of TSPO-related signal may be present
not only inside active plaques but also in distant re-
gions, reflecting axonal damages and the consequent
anterograde, retrograde, or trans-synaptic degeneration
of nearby neurons or in other brain areas where micro-
glia may play a role [12]. From PET-TSPO studies in
patients, it is known that the highest concordance
between TSPO-PET and MRI is around gadolinium-
enhancing T1-weighted lesions, which contain infiltrat-
ing immune cells, or in T2 hyperintense areas [12].
However, intense 11C-PK11195 uptake are present also
around T1-weighted hypointense lesions, the so-called
black holes, during relapse or in progressive MS pa-
tients [33]. This observation, already described by
Banati in 2000 [12], strongly indicates that PET-positive
T1 black holes are linked with an inflammatory state,
thus supporting the potential use of TSPO-PET as a
marker of disease progression [33]. In addition, in MS
patients, increased TSPO ligand binding has been de-
scribed in normal appearing WM or GM regions or
around the rim of chronic active T2 plaques. These find-
ings confirm the potential independent role of microglial
cells in MS and prompt the need to better explore the
potential diagnostic power of TSPO-PET [19, 34].
The concordance or discordance of MRI- and PET-
based abnormalities can be of particular relevance in some
areas, for instance the hippocampus, which is involved in
cognitive processes such as memory, known to be im-
paired in MS [10]. According to recent data, neurotoxic
molecules released by activated immune cells might inter-
fere with synaptic plasticity leading to cognitive dysfunc-
tions that are typical not only in EAE mice but also in MS
patients [16]. Of note, in both patients and animal models,
neuroimaging or post mortem studies demonstrated the
presence of hippocampal atrophy involving particularly
the CA1 sub-region [33, 35–37]. In the hippocampus,
according to some authors, soluble mediators released by
microglia contribute to the degeneration of GABAergic
interneurons which, in turn, could influence synaptic and
cognitive function in the hippocampus of EAE mice
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[36, 38]. On the other hand, several reports indicated
that activated resident microglia have a general role
in neuronal injury during MS and EAE and that
microglia neurotoxicity seems to involve glutamate-
driven excitotoxicity [39, 40].
For these reasons, the possibility to measure in vivo
regional microglia activation at single animal level and
to differentiate active inflammation from axonal damage
in critical regions involved in cognitive processes may be
particularly relevant. However, limits due to the low
spatial resolution in preclinical PET imaging together
with the high heterogeneous distribution of lesions
should be carefully considered when TSPO ligands are
used to track treatment effects in in vivo quantitative
studies in mice.
Conclusion
In conclusion, our ex vivo findings indicate that (i) 18F-
VC701 allows to measure the presence of activated im-
mune system cells in the brain and spinal cord of EAE
mice, (ii) results from in vivo TSPO-PET and MRI give
complementary information also in preclinical model of
MS and their combined use represents a fundamental
tool to better characterize the complex pathophysiology
of MS, and (iii) the heterogeneous distribution of lesions
together with the limited spatial resolution of PET
should be carefully considered when TSPO ligands are
used to track treatment effects in in vivo quantitative
studies in mice.
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Additional file 3: Figure S3. 18F-VC701 PET images of control and EAE
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